Home/Blog/ARS Pharmaceuticals News FDA Approval: Live Tracker
BLOG

ARS Pharmaceuticals News FDA Approval: Live Tracker

By , founder · Published · 10 min read

Key takeaways

  • The FDA approved neffy, the first epinephrine nasal spray for severe allergic reactions, in August 2024, covering adults and children weighing 30 kg or more.
  • PDUFA dates are officially published in the company's 8-K announcing NDA acceptance and in FDA approval or Complete Response Letters, not on third-party sites.
  • CRLs and advisory committee votes produce the largest tradeable gaps because they invalidate the base case, while scheduled PDUFA binaries are more priced in.
  • Small-cap pharma names gap on the headline and fade or extend within minutes, so the first 5 to 10 percent of the move is often priced in before confirmation.
  • Size FDA decisions for the worst open, not the average move, and cut normal position size by half or more into a PDUFA date.

This page tracks ARS Pharmaceuticals news FDA approval events as they break, with the next PDUFA decision date, plain-English impact breakdowns for approval versus CRL outcomes, and comparable small-cap pharma catalysts. If you trade the initial move, you get the decision date and the expected price behavior before the catalyst, not a recap after the move is priced in.

What is the latest FDA approval news for ARS Pharmaceuticals?

The most recent major FDA action on ARS Pharmaceuticals (SPRY) was the approval of neffy, the first epinephrine nasal spray for severe allergic reactions, in August 2024. The company has since pursued follow-on regulatory actions, including label expansions and additional indications, rather than a single one-and-done approval event.

Current status of the neffy label and follow-on regulatory actions

The initial approval covered adults and children weighing 30 kg or more for anaphylaxis. Subsequent milestones traders watch are label expansions (younger pediatric populations) and new indication filings, each of which carries its own review timeline and price-moving potential. Treat every follow-on action as a separate catalyst with its own date, not as an extension of the original approval.

How to verify the news against the primary source (FDA and company PR)

Check the FDA's official site for the approval letter or announcement naming ARS Pharmaceuticals and neffy directly, then cross-reference the company's own PR. If a headline on X or Discord cites no primary source, the first 5 to 10 percent of the move may already be priced in before you confirm it.

When is ARS Pharmaceuticals' next FDA decision date (PDUFA date)?

The next known regulatory catalyst for ARS Pharmaceuticals is tracked on its FDA calendar, and the honest answer changes as the company files new applications or responds to agency feedback. neffy (epinephrine nasal spray) already cleared review, so future dates depend on label expansions, additional indications, or Complete Response Letter items. Treat any date you see on third-party sites as unconfirmed until it appears in an official filing.

Upcoming decision-date calendar for ARS and peers

The calendar pairs ARS with comparable small-cap pharma names so you can see clustered catalyst risk across the sector. Dates below are illustrative placeholders; verify each against SEC filings before positioning.

TickerCompanyNext milestone typeStatus
SPRYARS PharmaceuticalsLabel expansion reviewVerify in 10-Q
VRTXVertexPipeline milestoneVerify in filings
TNXPTonixFDA interactionVerify in filings
CNSCNS PharmaceuticalsTrial milestoneVerify in filings

How PDUFA dates are set and where they are officially published

A PDUFA date is the FDA's goal date for a decision, set when the agency accepts an NDA for filing, typically ten months after submission. The official sources are the company's 8-K announcing acceptance and the FDA's approval letters and Complete Response Letters. Real-time alerts work the same way across tickers, whether you are watching an NDA decision or an AAPL earnings print: the catalyst hits the wire first, price follows.

How did the FDA approval affect ARS Pharmaceuticals' stock price?

SPRY's path to approval shows both sides of the catalyst trade. The company first received a complete response letter, which sent the stock down hard, then won approval for neffy (epinephrine nasal spray) in August 2024, with the stock repricing sharply higher on the news. Per ARS Pharmaceuticals' own announcement, the approval covered the first needle-free epinephrine option for allergic reactions, which is why the move was violent rather than gradual.

Trading the initial move: approval vs complete response letter

An approval and a CRL are mirror-image catalysts: same decision date, opposite sign, similar speed. Traders who wait for confirmation of direction give up the first leg either way.

Why the first minutes carry most of the repricing

Small-cap pharma gaps on the headline and then fades or extends within minutes. If you're watching NQ or ES for macro catalysts, the same logic applies — the edge is in sub-minute delivery, which is what we built Tradar's market news alerts for.

How does ARS Pharmaceuticals compare to Vertex, Tonix, CNS, and Milestone on FDA milestones?

Scanning peers side by side tells you whether a catalyst is idiosyncratic or part of a sector-wide risk tone. ARS Pharmaceuticals is a single-asset story where one FDA decision drives the tape, so position sizing has to assume the whole thesis is on the line at each date. Vertex is a large-cap with a deep pipeline, so any single FDA event moves it less, and its decisions function as sentiment inputs rather than survival events. Tonix, CNS Pharmaceuticals, and Milestone Pharmaceuticals sit closer to ARS on the risk curve: smaller caps, thinner cash runways, and FDA outcomes that can reprice the stock in one session. That spread matters because a CRL at a peer can drag your name down on contagion even when your company has no news of its own, which is why the practical workflow is to rank all five names' catalysts by how binary the outcome is before you size anything.

Vertex Pharmaceuticals: FDA milestones that matter

For Vertex, FDA milestones are pipeline checkpoints rather than survival events. A decision on one program rarely reprices the whole company, but a surprise complete response letter can still shake the sector and drag small-cap pharma with it. Watch it as a sentiment input.

Tonix Pharmaceuticals: FDA milestones that matter

Tonix trades like the small-cap peers: FDA feedback, study starts, and decision dates each carry outsized weight relative to market cap. Read its milestones the same way you read ARS's, as binary events where the initial move happens in the first minutes. If you run alerts across several of these names at once, a tool comparison like NewsEdge vs the alternatives is worth scanning for latency differences, because a peer's FDA headline can move your position even when your name has no news.

CNS Pharmaceuticals and Milestone Pharmaceuticals: FDA milestones that matter

CNS and Milestone both fit the pattern where an FDA interaction, a designated milestone, or a decision window is the dominant catalyst on the calendar. The practical move is to stack all five names' dates on one calendar and rank them by how binary the outcome is. ARS, CNS, and Milestone events tend to trade as coin flips with fat tails; Vertex events trade as drift. That ranking decides position size before the headline hits, not after you have already given back the first 5 to 10 percent of the move.

What regulatory milestones should traders watch for small-cap pharma stocks?

Approval is one event type in a longer chain. Small-cap pharma catalysts include PDUFA decision dates, advisory committee meetings, complete response letters (CRLs), label expansion decisions, and trial data readouts. Each one resets expectations, and each one can reprice a stock in minutes.

PDUFA dates, advisory committee meetings, and CRLs

A PDUFA date is the FDA's goal date for acting on an application, set under the user fee program that funds faster review timelines. Advisory committee meetings often precede a decision and frequently move the stock before the PDUFA date arrives. A CRL is the negative outcome: the FDA declines approval and issues deficiencies, which is where the worst gaps happen.

Which milestone types produce tradeable gaps

CRLs and advisory committee votes produce the largest gaps because they invalidate the base case outright. PDUFA dates produce gaps too, but the binary is more priced in by then. Label expansions and readouts tend to move smaller caps hardest because volume is thin and expectations are less anchored.

The edge is timing, not coverage. By the time a creator posts a video about the catalyst, the first 5 to 10 percent of the move is already priced in, which is why Tradar pushes sub-minute alerts so you reach the primary source first. The same logic applies across catalyst-driven names, not just pharma — see how we covered a bank-specific event in our WFC news tracker.

What is the FDA approval process timeline for new drug applications?

From NDA submission to PDUFA date

Once a company submits an NDA or BLA, the FDA has 60 days to decide whether to file it. Filing starts the review clock, which ends at the PDUFA date: ten months from submission for standard review, six months for priority. The decision usually lands on or near that date, sometimes weeks early, so the window matters more than the exact day.

Priority review, standard review, and what changes the clock

Priority review shortens the clock to six months and often signals the FDA sees an unmet need, which is why the designation itself can move a small-cap stock. Complete Response Letters, CRLs, reset expectations without killing the drug. Advisory committee meetings, manufacturing pre-approval inspections, and information requests can all push a PDUFA date out, so traders track FDA calendar updates rather than assuming the original date holds.

How can traders set up alerts for FDA approval news?

What a good FDA alert needs: speed, source, and impact context

An FDA alert is only tradeable if it hits in under a minute, links to the primary source (the company press release or the FDA announcement), and tells you whether the decision was expected. An approval that was fully priced in can fade; a CRL nobody saw coming can gap a small-cap 40%. Context matters as much as speed.

Comparing alert tools for biotech catalysts

Free options like Yahoo Finance and CNBC push headlines fast but rarely flag whether an event was a PDUFA decision or a surprise filing. Seeking Alpha adds analysis, though often after the move. The honest test: does the alert arrive before FinTwit is quoting the press release, and does it say what changed?

How Tradar handles FDA and regulatory alerts

Run Tradar through the same three criteria. Speed: alerts target sub-minute delivery from the primary source. Source: each alert ties back to the underlying company release, the same filings traders can verify on SEC EDGAR. Impact: Tradar adds plain-English context on what an approval, CRL, or milestone means for the stock and comparable peers, so you trade the catalyst with the setup already framed.

How do traders position around FDA decision dates without getting chopped up?

Sizing binary events and gap risk

Treat an FDA decision as a gap event, not an intraday setup. Size for the worst open, not the average move: if a small-cap pharma name can gap 40% either way overnight, your position has to survive the adverse print without a stop getting blown through. Many catalyst traders cut normal size by half or more into a PDUFA date, or flat-out hold no overnight exposure and trade only the reaction.

Pre-market liquidity is thin on these names. If you must act before the open, use limit orders and expect slippage; the first print is often the worst fill of the session.

Reading the tape when the headline hits

The trap is buying the headline after the first 5 to 10% of the move is already priced in. Watch how price behaves on the first pullback after the initial spike: acceptance above the pre-headline range confirms the catalyst, immediate rejection means the move is done. Volume matters more than the headline wording — approval on fading volume usually fades.

Sub-minute alerts only help if your plan for the first two candles is written before the catalyst hits. Decide your entry, invalidation, and size in advance, then let the tape tell you which scenario you're in.

FAQ

Is ARS Pharmaceuticals' neffy approved by the FDA?

Yes. The FDA approved neffy, the first epinephrine nasal spray for severe allergic reactions, in August 2024, covering adults and children weighing 30 kg or more. The company has since pursued follow-on actions such as younger pediatric label expansions and new indication filings, so treat each subsequent regulatory action as its own catalyst with a separate review timeline.

What does a complete response letter mean for a small-cap pharma stock?

A CRL means the FDA declined approval and issued deficiencies, which is where the worst gaps happen. ARS Pharmaceuticals itself received one before ultimately winning approval, and the stock fell hard on the news. Because a CRL invalidates the base case outright, it produces larger tradeable gaps than a scheduled PDUFA date, where the binary is usually more priced in.

Do FDA approval decisions come out before market open or after hours?

Decisions usually land on or near the PDUFA date, sometimes weeks early, and the exact timing within the day is not guaranteed. Many announcements hit before the open, which is why small-cap pharma names gap rather than drift intraday. Pre-market liquidity is thin, so if you act early, use limit orders and expect the first print to be a poor fill.

Where can I find official PDUFA dates instead of secondhand tweets?

The company's 8-K announcing NDA acceptance and the FDA's approval letters and Complete Response Letters are the primary sources. A PDUFA date is set when the agency accepts an application, typically ten months after submission. Treat any date you see on third-party sites or social media as unconfirmed until it appears in an official filing you have read yourself.

How fast do biotech stocks move after an FDA approval headline?

The first minutes carry most of the repricing. Small-cap names gap on the headline and then fade or extend within minutes, and the first 5 to 10 percent of the move can be priced in before you confirm a primary source. Watch price behavior on the first pullback: acceptance above the pre-headline range confirms the catalyst, immediate rejection means the move is done.

Get the catalyst before it's priced in

Real-time alerts from 190+ active sources — SEC, FDA, the Fed — scored for impact and pushed to your phone.

Get Alerts